Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein

Molecular Diversity

Volumn 2, Issue 1-2, 1996, Pages 119-124

  Ley, Arthur Charles ^a   Markland, William ^a,b   Ladner, Robert Charles ^a  

^a Protein Engineering Corporation   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Combinatorial library; Kunitz domain; LACI; Plasma kallikrein; Plasmin; Screening; Specificity

Indexed keywords

KALLIKREIN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PEPTIDE LIBRARY; PLASMIN; SERINE PROTEINASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; DRUG ANTAGONISM; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; HUMANS; KALLIKREINS; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PLASMIN; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPSIN INHIBITOR, KUNITZ SOYBEAN;

EID: 0030252583     PISSN: 13811991     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01718709     Document Type: Article

References (26)

1. Robbins, K.C., The plasminogen-plasmin enzyme system, In Colman, R.W., Hirsh, J., Marder, V.J. and Salzman, E.W. (Eds.) Hemostasis and Thrombosis, 2nd ed., J.B. Lippincott Company, Philadelphia, PA, U.S.A., 1987, pp. 340-357.
2. Schmaier, A.H., Silverberg, M., Kaplan, A.P. and Colman, R.W., Contact activation and its abnormalities, In Colman, R.W., Hirsh, J., Marder, V.J. and Salzman, E.W. (Eds.) Hemostasis and Thrombosis, 2nd ed., J.B. Lippincott Company, Philadelphia, PA, U.S.A., 1987, pp. 18-38.
3. Royston, D., Bidstrup, B.P., Taylor, K.M. and Sapsford, R.N., Effect of aprotinin on need for blood transfusion after repeat open-heart surgery, Lancet 2, (1987) 1289-1291.
4. Bidstrup, B.P., Royston, D., Sapsford, R.N. and Taylor, K.M., Reduction in blood loss and blood use after cardiopulmonary bypass high dose aprotinin (trasylol), J. Thorac. Cardiovasc. Surg., 97 (1989) 364-372.
5. Royston, D., Aprotinin therapy, Br. J. Anaesth., 73 (1994) 734-737.
6. Wildevuur, Ch.R.H., Eijsman, L., Roozendaal, K.J., Harder, M.P., Chang, M. and Van Oeveren, W., Platelet preservation during cardiopulmonary bypass with aprotinin, Eur. J. Cardio-Thorac Surg., 3 (1989) 533-538.
7. Wachtfogel, Y.T., Kucich, U., Hack, C.E., Gluszko, P., Niewiarowski, S., Colman, R.W. and Edmunds Jr., L.H., Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion, J. Thorac. Cardiovasc. Surg., 106 (1993) 1-10.
8. Wachtfogel, Y.T., Hack, C.E., Nuijens, J.H., Kettner, C., Reilly, T.M., Knabb, R.M., Bischoff, R., Tschesche, H., Wenzel, H., Kucich, U., Edmunds Jr., L.H. and Colman, R.W., Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation, Am. J. Physiol., 268 (1995) H1352-H1357.
9. Cumming, A.D., Acute renal failure and sepsis: Therapeutic approaches, Nephrol. Dial. Transplant., 9 Suppl. 4 (1994) 159-163.
10. Ladner, R.C. and Guterman, S.K., Patent Application: Directed Evolution of Novel Binding Proteins, WO90/02809, 1990.
11. Smith, G.P. and Scott, J.K., Libraries of peptides and proteins displayed on filamentous phage, Methods Enzymol., 217 (1993) 228-257.
12. Clackson, T. and Wells, J.A., In vitro selection from protein and peptide libraries, Trends Biotechnol., 12 (1994) 173-184.
13. Markland, W., Roberts, B.L. and Ladner, R.C., Selection for protease inhibitors using bacteriophage display, Methods Enzymol., 263 (1996) 28-51.
14. Markland, W., Roberts, B.L., Saxena, M.J., Guterman, S.K. and Ladner, R.C., Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13, Gene, 109 (1991) 13-19.
15. Roberts, B.L., Markland, W., Ley, A.C., Kent, R.B., White, D.W., Guterman, S.K. and Ladner, R.C., Directed evolution of a protein: Selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage, Proc. Natl. Acad. Sci. USA, 89 (1992) 2429-2433.
16. Roberts, B.L., Markland, W., Siranosian, K., Saxena, M.J., Guterman, S.K. and Ladner, R.C., Protease inhibitor display M13 phage: Selection of high-affinity neutrophil elastase inhibitors, Gene, 121 (1992) 9-15.
17. a. I. Potent inhibitors selected from libraries by phage display, J. Biol. Chem., 269 (1994) 22129-22136.
18. a. II. Potent and specific inhibitors by competitive phage selection, J. Biol. Chem., 269 (1994) 22137-22144.
19. Dennis, M.S., Herzka, A. and Lazarus, R.A., Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display, J. Biol. Chem., 270 (1995) 25411-25417.
20. Hynes, T.R., Randal, M., Kennedy, L.A., Eigenbrot, C. and Kossiakoff, A.A., X-ray crystal structure of the protease inhibitor domain of Alzheimer's amyloid beta-protein precursor, Biochemistry, 29 (1990) 10018-10022.
21. Ladner, R.C., In Kay, B., Winter, J. and McCafferty, J. (Eds.), Phage Display of Peptides and Protein Domains: A Laboratory Manual, Academic Press, New York, NY, U.S.A., 1996, pp. 151-189.
22. Clackson, T. and Wells, J.A., A hot spot of binding energy in a hormone-receptor interface, Science, 267 (1995) 383-386.
23. Wells, J.A., Additivity of mutational effects in proteins, Biochemistry, 29 (1990) 8509-8517.
24. Markland, W., Lee, S.W., Ley, A.C. and Ladner, R.C., Iterative optimization of high-affinity protease inhibitors using phage display. 1. Plasmin, Biochemistry, 35 (1996) 8045-8057.
25. Markland, W., Ley, A.C. and Ladner, R.C., Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin, Biochemistry, 35 (1996) 8058-8067.
26. Schlechter, I. and Berger, A., On the active site of proteases. III. Mapping the active site of papain; specific peptide inhibitors of papain, Biochem. Biophys. Res. Commun., 32 (1968) 898-902.